Enovis Co. (NYSE:ENOV) Receives Average Recommendation of "Moderate Buy" from Analysts

Enovis Co. (NYSE:ENOV - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $67.00.

Several research firms recently commented on ENOV. Evercore ISI dropped their price target on shares of Enovis from $62.00 to $58.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 1st. Needham & Company LLC dropped their target price on shares of Enovis from $82.00 to $65.00 and set a "buy" rating on the stock in a research report on Thursday, August 8th. JPMorgan Chase & Co. dropped their target price on shares of Enovis from $53.00 to $50.00 and set a "neutral" rating on the stock in a research report on Thursday, August 8th. Finally, JMP Securities started coverage on shares of Enovis in a research report on Thursday, October 3rd. They issued an "outperform" rating and a $62.00 target price on the stock.

Hedge Funds Weigh In On Enovis

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Fidelis Capital Partners LLC purchased a new position in Enovis during the first quarter worth about $34,000. Ridgewood Investments LLC purchased a new position in Enovis during the second quarter worth about $44,000. DekaBank Deutsche Girozentrale purchased a new position in Enovis during the third quarter worth about $55,000. Innealta Capital LLC purchased a new position in Enovis during the second quarter worth about $65,000. Finally, Benjamin F. Edwards & Company Inc. raised its stake in Enovis by 28.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company's stock worth $76,000 after purchasing an additional 371 shares during the period. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Stock Performance

Shares of Enovis stock traded up $0.45 during trading on Friday, hitting $39.99. 641,780 shares of the company's stock were exchanged, compared to its average volume of 565,981. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 2.26. The business has a 50-day simple moving average of $42.58 and a 200-day simple moving average of $46.45. Enovis has a 52-week low of $38.27 and a 52-week high of $65.03. The stock has a market capitalization of $2.19 billion, a price-to-earnings ratio of -26.66 and a beta of 1.91.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.59 by $0.03. The company had revenue of $525.20 million for the quarter, compared to analyst estimates of $525.99 million. Enovis had a negative net margin of 4.73% and a positive return on equity of 4.06%. The firm's revenue was up 22.6% on a year-over-year basis. During the same quarter last year, the business earned $0.61 earnings per share. On average, research analysts forecast that Enovis will post 2.7 EPS for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.